Spondyloarthritis & psoriatic arthritis
Incidence of Uveitis in Patients With Axial Spondylarthritis Treated With Biologics or Targeted Synthetics: A Systematic Review and Network Meta‐Analysis
Authors' conclusion
Anti-TNF mAbs, JAKi, and anti-IL-17 appear protective against AU events in individuals with AxSpA, with no significant differences in risk of AU between treatments.
Study context
- Population
- Patients with axSpA in phase II/III double-blinded RCTs44 trials
- Comparison
- Anti-TNF monoclonal antibodies (mAb), etanercept, anti-IL-17 and Janus kinase inhibitors (JAKi) vs placebo
- Outcome
- Risk of anterior uveitis (IRR vs placebo, network meta-analysis (NMA)); Incidence rate (IR) of AU/100 person-years
Methodological detailsphase II/III double-blinded RCTs, random effects, per-protocol patient-exposure years (PEY), Cochrane Risk of Bias-2
- Phase II/III double-blinded RCTs
- Random effects
- Per-protocol PEY
- Cochrane Risk of Bias-2
Pooled result
As reported in the abstract
Anterior uveitis, IR/100 person-years and IRR vs placebo (NMA)
Each group vs placeboIncidence rate ratio (95% CI)
Anti-TNF mAb
0.32(0.10–1.04)
Etanercept
0.42(0.08–2.38)
Anti-IL-17
0.43(0.19–0.98)
JAKi
0.32(0.06–1.67)
Original publication
Incidence of Uveitis in Patients With Axial Spondylarthritis Treated With Biologics or Targeted Synthetics: A Systematic Review and Network Meta‐Analysis. Arthritis Rheumatol. Published 13 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →